Market Overview

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Share:
Related BIIB
Baird Still Isn't Buying Biogen
15 Biggest Mid-Day Gainers For Thursday
Roche's hemophilia candidate emicizumab shows encouraging results in early-stage study (Seeking Alpha)
Related AMGN
Barclays Says Acceleration For Amgen Could Be A Challenge
12 Must Watch Stocks for July 27, 2016
Global Leaders Trinseo, Atlassian Set To Report, But Expectations Differ (Investor's Business Daily)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.

Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.

Posted-In: Biotechnology Industry Highest EPS Estimates NASDAQ StocksTrading Ideas

 

Related Articles (AMGN + BIIB)

View Comments and Join the Discussion!